Science

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Arndt Vogel/X

Apr 1, 2025, 11:25

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared an article by Daniel H. Palmer, et al. on X:

“Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Supports GemCap for R0 & lymph node-negative patients not eligible for mFOLFIRINOX.”

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Authors: Daniel H. Palmer, et al.

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Adjuvant Therapy Arndt Vogel cancer Daniel H. Palmer 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 ESPAC4 fight against cancer Gastroenterology Global fight against cancer Hannover Medical School Hepatology mFOLFIRINOX OncoDaily Oncology pancreatic adenocarcinoma

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth